Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection

被引:44
作者
Loomis-Price, LD
Cox, JH
Mascola, JR
VanCott, TC
Michael, NL
Fouts, TR
Redfield, RR
Robb, ML
Wahren, B
Sheppard, HW
Birx, DL
机构
[1] HM Jackson Fdn, Walter Reed Army Inst Res, HIV Lab, Rockville, MD 20850 USA
[2] SRA Technol, Rockville, MD USA
[3] Aaron Diamond AIDS Res Ctr, New York, NY USA
[4] Swedish Inst Infect Dis Control, Stockholm, Sweden
[5] Karolinska Inst, Stockholm, Sweden
[6] Calif State Dept Hlth Serv, Berkeley, CA USA
关键词
D O I
10.1086/314436
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus (HIV)-1-infected rapid and slow progressors showed differential humoral responses against MV envelope peptides and proteins early in infection. Sera from slow progressors reacted more strongly with short envelope peptides modeling gp160(NL4-3), predominantly in gp41, Reactivity to six peptides (in constant regions C3, C4, and C5 of gp120 and in gp41) correlated with slower progression, In a novel association, reactivity to three peptides (in constant regions C1 and C3 and variable region V3 of gp120) correlated with faster progression. Envelope peptide reactivity correlated with subsequent course of disease progression as strongly as did reactivity to gag p24, Patients heterozygous for 32-bp deletions in the CCR5 coreceptor reacted more frequently to an epitope in gp41, Rapid progressors had greater gp120 native-to-denatured binding ratios than did slow progressors. White antibody-dependent cellular cytotoxicity against gp120 did not strongly differentiate the groups, slow progressors showed a broader neutralization pattern against 5 primary virus isolates.
引用
收藏
页码:1306 / 1316
页数:11
相关论文
共 60 条
[1]  
Baum LL, 1996, J IMMUNOL, V157, P2168
[2]   Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1 [J].
Binley, JM ;
Klasse, PJ ;
Cao, YZ ;
Jones, I ;
Markowitz, M ;
Ho, DD ;
Moore, JP .
JOURNAL OF VIROLOGY, 1997, 71 (04) :2799-2809
[3]  
Birx Deborah L., 1996, P222
[4]   Analyses of functional antibody responses in HIV-1-infected individuals after vaccination with rgp160 [J].
Broliden, K ;
Hinkula, J ;
Bratt, G ;
Persson, C ;
Otero, A ;
Ekstrom, A ;
Sandstrom, E ;
Broliden, PA ;
Wahren, B .
CLINICAL AND DIAGNOSTIC VIROLOGY, 1996, 6 (2-3) :115-126
[5]  
BROLIDEN K, 1993, CLIN EXP IMMUNOL, V93, P56
[6]   IDENTIFICATION OF HUMAN NEUTRALIZATION-INDUCING REGIONS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE GLYCOPROTEINS [J].
BROLIDEN, PA ;
VONGEGERFELT, A ;
CLAPHAM, P ;
ROSEN, J ;
FENYO, EM ;
WAHREN, B ;
BROLIDEN, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (02) :461-465
[7]   VIROLOGICAL AND IMMUNOLOGICAL CHARACTERIZATION OF LONG-TERM SURVIVORS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION [J].
CAO, YZ ;
QIN, LM ;
ZHANG, LQ ;
SAFRIT, J ;
HO, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :201-208
[8]  
Carter J M, 1994, Methods Mol Biol, V36, P207
[9]   ANTIBODIES TO A PUTATIVE HIV GP41 IMMUNOSUPPRESSIVE PEPTIDE, PHIVIS (583-599), DO NOT CORRELATE SIGNIFICANTLY WITH OUTCOME IN HIV-INFECTION [J].
CHEINGSONGPOPOV, R ;
PANAGIOTIDI, C ;
CAUN, K ;
KLASSE, PJ ;
PIPKORN, R ;
BLOMBERG, J ;
WEBER, J .
AIDS, 1990, 4 (03) :251-253
[10]   RELATION BETWEEN HUMORAL RESPONSES TO HIV GAG AND ENV PROTEINS AT SEROCONVERSION AND CLINICAL OUTCOME OF HIV-INFECTION [J].
CHEINGSONGPOPOV, R ;
PANAGIOTIDI, C ;
BOWCOCK, S ;
ARONSTAM, A ;
WADSWORTH, J ;
WEBER, J .
BMJ-BRITISH MEDICAL JOURNAL, 1991, 302 (6767) :23-26